Olema Pharmaceuticals Inc.

3 trials 3 recruiting Commercial sponsor

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

3 Recruiting

0 Completed trials

15 Countries active

9 Unique IMPs

N/A Results reported

Phase III

Phase I

Phase III: 2 Phase I: 1

Top IMPs

OP-1250 2 PALAZESTRANT 2

All trials

3 total

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors Recruiting

2025-523686-15-00 Phase I 3 countries
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting

2025-522873-12-00 Phase III 13 countries OP-1250; PALAZESTRANT
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 Phase III 13 countries OP-1250; PALAZESTRANT

Showing 1–3 of 3 trials

← All sponsors A–Z